Although both DGAT1 and DGAT2 catalyze the same reaction in the last step of triglyceride synthesis, often in the same cells, DGAT1 but not DGAT2 has been pursued for more than a decade as a therapeutic target for obesity and metabolic disorders such as insulin resistance. The gene discussed is DGAT1; the disease is metabolic disease.